Aymen Al-Shamkhani

7PUBLICATIONS
38CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityTissue engineering
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Dec 20, 2025
Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapy.

Marcus A Widdess, Anastasia Pakidi, Hannah J Metcalfe

|Sep 08, 2025
CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial.

Lara E Buermann, Louise Stanton, Matthew J J Rose-Zerilli

|Dec 28, 2023
Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges.

Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani

|Mar 04, 2020
NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors.

Kirsty Ford, Christopher J Hanley, Massimiliano Mellone

|Jan 17, 2018
Cleavage of TL1A Differentially Regulates Its Effects on Innate and Adaptive Immune Cells.

John R Ferdinand, Arianne C Richard, Françoise Meylan

|Nov 10, 2017
The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy.

Sarah L Buchan, Anne Rogel, Aymen Al-Shamkhani

Pageof 2

Frequent Collaborators

3 joint publications

Mark S Cragg

3 joint publications

Sean H Lim

2 joint publications

Stephen A Beers

1 joint publications

Sonya James